Psoriasis is a skin disease which results in scales on the skin caused by flaky patches. Psoriasis is triggered by various conditions such as drug reactions, trauma, and skin infection etc. Globally, there are 125 million people affected by psoriasis and yet there is no effective treatment available, and it emphasizes the need for discovery of efficacious treatments. De-novo drug development takes 10∼17 years and $2∼$3 billion of investment with less than 10% success rate to bring drug from concept to a market ready product. A possible alternative is drug repurposing, which aims at finding other indications of already approved drugs. In this study, a computational drug repurposing framework is developed and applied to differential gene expressions of Psoriasis targets obtained from the publicly available database (GEO). This strategy uses the gene expression signatures of the Psoriasis and compares it with perturbagen available in the CMap. Based on the connected signature drugs are ranked which could possibly reverse the signatures to stop the psoriasis. The drugs with most negative connectivity scores are ranked efficient and vice versa. The top hit drugs are verified using the literature survey of the peer reviewed journal, electronic health records, patents, and hospital database. As a result, 50/150 and 37/150 drugs are confirmed to have anti-psoriasis efficacy in two datasets. Top 10 drugs are suggested as potential repurposable drugs for psoriasis. This study offers, a powerful yet simple approach for rapid identification of potential drug repurposing candidates in Psoriasis and any disease of interest.

牛皮癣是一种皮肤病，会导致由片状斑块引起的皮肤鳞屑。银屑病是由药物反应、外伤、皮肤感染等多种情况引发的。全球有1.25亿人患有银屑病，但目前尚无有效的治疗方法，这凸显了寻找有效治疗方法的必要性。从头药物开发需要 10 至 17 年的时间和 2 至 30 亿美元的投资，成功率不到 10%，才能将药物从概念变成上市产品。一种可能的替代方案是药物再利用，其目的是寻找已批准药物的其他适应症。在这项研究中，开发了一种计算药物再利用框架，并将其应用于从公共数据库 (GEO) 中获得的银屑病靶标的差异基因表达。该策略使用银屑病的基因表达特征并将其与 CMap 中可用的扰动剂进行比较。根据相关的签名药物进行排名，这些药物可能会逆转签名以阻止牛皮癣。具有最多负连通性分数的药物被评为有效，反之亦然。使用同行评审期刊的文献调查、电子健康记录、专利和医院数据库来验证热门药物。结果，50/150 和 37/150 药物在两个数据集中被证实具有抗银屑病功效。建议将前 10 种药物作为银屑病的潜在可再利用药物。本研究提供了一种强大而简单的方法，用于快速识别银屑病和任何感兴趣疾病的潜在药物再利用候选药物。